Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
(Stage 1: Public Comment Profiles)
m (Stage 2: Consensus Profiles)
Line 32: Line 32:
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
*[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]]
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| Atherosclerosis Biomarkers by (C)CTA - Imaging Profile 2020-03-10]]
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===

Revision as of 13:50, 1 June 2020

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

  • Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
  • Assessment Procedures (refer to Section 4 in the Profile document - pg 30)

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form

Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL


QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement

See Also